OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis

Sherine Gabriel, Michael Drummond, Andreas Maetzel, Maarten Boers, Doug Coyle, Vivian Welch, Peter Tugwell

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Standardization of methods for economic evaluation is essential for defining the methodological research agenda that will advance the discipline. Standardization also greatly facilitates the interpretation and comparison of the results of economic analyses. For these reasons, several jurisdictions now require economic evaluation, conducted according to standardized methodological guidelines, as a key ingredient in decision making for reimbursement of health treatments and technologies. The application of these general guidelines, however, can be difficult in the absence of disease-specific information. In the case of rheumatoid arthritis (RA), the recent emergence of innovative, highly effective, but also expensive treatments has created an immediate need to more fully understand the economic implications of RA treatments. With this background, the OMERACT Economics Working Group. set out in 1994 to develop an RA-specific reference case for economic evaluation. This report summarizes the OMERACT process leading to specific recommendations on the 12 key elements of a proposed "reference case" for economic evaluation in RA. These elements include: study horizon, duration of therapy, extrapolation beyond trial duration, modeling beyond therapy, synthesis of comparisons where head-to-head trials do not exist, clinical outcome measures, mortality, valuation of health states, resource utilization, discontinuation of therapy, therapeutic sequence, and population risk stratification. Through these efforts, the OMERACT Economics Working Group aims to expedite and enhance the conduct and dissemination of methodological research in economic analyses in the rheumatic diseases.

Original languageEnglish (US)
Pages (from-to)886-890
Number of pages5
JournalJournal of Rheumatology
Volume30
Issue number4
StatePublished - Apr 1 2003

Fingerprint

Cost-Benefit Analysis
Rheumatoid Arthritis
Economics
Guidelines
Biomedical Technology
Health Resources
Therapeutics
Rheumatic Diseases
Research
Decision Making
Outcome Assessment (Health Care)
Mortality
Population

Keywords

  • Economic evaluation
  • OMERACT
  • Reference case

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Gabriel, S., Drummond, M., Maetzel, A., Boers, M., Coyle, D., Welch, V., & Tugwell, P. (2003). OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. Journal of Rheumatology, 30(4), 886-890.

OMERACT 6 Economics Working Group report : A proposal for a reference case for economic evaluation in rheumatoid arthritis. / Gabriel, Sherine; Drummond, Michael; Maetzel, Andreas; Boers, Maarten; Coyle, Doug; Welch, Vivian; Tugwell, Peter.

In: Journal of Rheumatology, Vol. 30, No. 4, 01.04.2003, p. 886-890.

Research output: Contribution to journalArticle

Gabriel, S, Drummond, M, Maetzel, A, Boers, M, Coyle, D, Welch, V & Tugwell, P 2003, 'OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis', Journal of Rheumatology, vol. 30, no. 4, pp. 886-890.
Gabriel S, Drummond M, Maetzel A, Boers M, Coyle D, Welch V et al. OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis. Journal of Rheumatology. 2003 Apr 1;30(4):886-890.
Gabriel, Sherine ; Drummond, Michael ; Maetzel, Andreas ; Boers, Maarten ; Coyle, Doug ; Welch, Vivian ; Tugwell, Peter. / OMERACT 6 Economics Working Group report : A proposal for a reference case for economic evaluation in rheumatoid arthritis. In: Journal of Rheumatology. 2003 ; Vol. 30, No. 4. pp. 886-890.
@article{ff9d99415f2844d187a9d7008f905fdc,
title = "OMERACT 6 Economics Working Group report: A proposal for a reference case for economic evaluation in rheumatoid arthritis",
abstract = "Standardization of methods for economic evaluation is essential for defining the methodological research agenda that will advance the discipline. Standardization also greatly facilitates the interpretation and comparison of the results of economic analyses. For these reasons, several jurisdictions now require economic evaluation, conducted according to standardized methodological guidelines, as a key ingredient in decision making for reimbursement of health treatments and technologies. The application of these general guidelines, however, can be difficult in the absence of disease-specific information. In the case of rheumatoid arthritis (RA), the recent emergence of innovative, highly effective, but also expensive treatments has created an immediate need to more fully understand the economic implications of RA treatments. With this background, the OMERACT Economics Working Group. set out in 1994 to develop an RA-specific reference case for economic evaluation. This report summarizes the OMERACT process leading to specific recommendations on the 12 key elements of a proposed {"}reference case{"} for economic evaluation in RA. These elements include: study horizon, duration of therapy, extrapolation beyond trial duration, modeling beyond therapy, synthesis of comparisons where head-to-head trials do not exist, clinical outcome measures, mortality, valuation of health states, resource utilization, discontinuation of therapy, therapeutic sequence, and population risk stratification. Through these efforts, the OMERACT Economics Working Group aims to expedite and enhance the conduct and dissemination of methodological research in economic analyses in the rheumatic diseases.",
keywords = "Economic evaluation, OMERACT, Reference case",
author = "Sherine Gabriel and Michael Drummond and Andreas Maetzel and Maarten Boers and Doug Coyle and Vivian Welch and Peter Tugwell",
year = "2003",
month = "4",
day = "1",
language = "English (US)",
volume = "30",
pages = "886--890",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "4",

}

TY - JOUR

T1 - OMERACT 6 Economics Working Group report

T2 - A proposal for a reference case for economic evaluation in rheumatoid arthritis

AU - Gabriel, Sherine

AU - Drummond, Michael

AU - Maetzel, Andreas

AU - Boers, Maarten

AU - Coyle, Doug

AU - Welch, Vivian

AU - Tugwell, Peter

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Standardization of methods for economic evaluation is essential for defining the methodological research agenda that will advance the discipline. Standardization also greatly facilitates the interpretation and comparison of the results of economic analyses. For these reasons, several jurisdictions now require economic evaluation, conducted according to standardized methodological guidelines, as a key ingredient in decision making for reimbursement of health treatments and technologies. The application of these general guidelines, however, can be difficult in the absence of disease-specific information. In the case of rheumatoid arthritis (RA), the recent emergence of innovative, highly effective, but also expensive treatments has created an immediate need to more fully understand the economic implications of RA treatments. With this background, the OMERACT Economics Working Group. set out in 1994 to develop an RA-specific reference case for economic evaluation. This report summarizes the OMERACT process leading to specific recommendations on the 12 key elements of a proposed "reference case" for economic evaluation in RA. These elements include: study horizon, duration of therapy, extrapolation beyond trial duration, modeling beyond therapy, synthesis of comparisons where head-to-head trials do not exist, clinical outcome measures, mortality, valuation of health states, resource utilization, discontinuation of therapy, therapeutic sequence, and population risk stratification. Through these efforts, the OMERACT Economics Working Group aims to expedite and enhance the conduct and dissemination of methodological research in economic analyses in the rheumatic diseases.

AB - Standardization of methods for economic evaluation is essential for defining the methodological research agenda that will advance the discipline. Standardization also greatly facilitates the interpretation and comparison of the results of economic analyses. For these reasons, several jurisdictions now require economic evaluation, conducted according to standardized methodological guidelines, as a key ingredient in decision making for reimbursement of health treatments and technologies. The application of these general guidelines, however, can be difficult in the absence of disease-specific information. In the case of rheumatoid arthritis (RA), the recent emergence of innovative, highly effective, but also expensive treatments has created an immediate need to more fully understand the economic implications of RA treatments. With this background, the OMERACT Economics Working Group. set out in 1994 to develop an RA-specific reference case for economic evaluation. This report summarizes the OMERACT process leading to specific recommendations on the 12 key elements of a proposed "reference case" for economic evaluation in RA. These elements include: study horizon, duration of therapy, extrapolation beyond trial duration, modeling beyond therapy, synthesis of comparisons where head-to-head trials do not exist, clinical outcome measures, mortality, valuation of health states, resource utilization, discontinuation of therapy, therapeutic sequence, and population risk stratification. Through these efforts, the OMERACT Economics Working Group aims to expedite and enhance the conduct and dissemination of methodological research in economic analyses in the rheumatic diseases.

KW - Economic evaluation

KW - OMERACT

KW - Reference case

UR - http://www.scopus.com/inward/record.url?scp=0037383447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037383447&partnerID=8YFLogxK

M3 - Article

C2 - 12672223

AN - SCOPUS:0037383447

VL - 30

SP - 886

EP - 890

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 4

ER -